Meropenem Plus Aztreonam Combination Therapy
Meropenem and aztreonam can be co-administered as a combined regimen. (pmc.ncbi.nlm.nih.gov) This combination has demonstrated in vitro synergy against selected multidrug-resistant Gram-negative pathogens, particularly metallo-β-lactamase–producing Enterobacterales, in experimental models. (pmc.ncbi.nlm.nih.gov)
Medication Selection Algorithm
- Monotherapy with a single active agent is preferred when the isolate is susceptible to an appropriate β-lactam regimen. (No guideline support found in retrieved sources for this specific question.)
- Meropenem plus aztreonam is a potential strategy when resistance mechanisms limit activity of standard β-lactams and combination synergy is demonstrated for the suspected resistance phenotype. (pmc.ncbi.nlm.nih.gov)
- For suspected metallo-β-lactamase–producing organisms, aztreonam-based combinations have been studied because aztreonam activity can be preserved in metallo-β-lactamase contexts, and synergy with carbapenem-containing backbones has been explored experimentally. (pmc.ncbi.nlm.nih.gov)
Key Evidence Supporting This Recommendation
- Checkerboard and time-kill experiments have shown synergistic activity for aztreonam combined with meropenem-containing regimens in subsets of metallo- and serine-β-lactamase–producing Enterobacterales isolates. (pmc.ncbi.nlm.nih.gov)
- Clinical experience describing meropenem/vaborbactam plus aztreonam for NDM-producing Klebsiella pneumoniae supports plausibility of aztreonam’s benefit when combined with a carbapenem backbone in this resistance class. (academic.oup.com)
Monotherapy Versus Combination Therapy
Combination therapy is considered when single-agent activity is expected to be insufficient and experimentally demonstrated synergy exists for the pathogen/resistance mechanism combination. (pmc.ncbi.nlm.nih.gov) The retrieved evidence base for meropenem plus aztreonam specifically is primarily experimental rather than definitive randomized clinical trial evidence. (pmc.ncbi.nlm.nih.gov)
Important Clarifications and Nuances
- Reported synergy for aztreonam combinations is not universal across all isolates. (pmc.ncbi.nlm.nih.gov)
- A related body of evidence includes aztreonam combined with meropenem/vaborbactam rather than meropenem alone, and the most directly supported clinical descriptions in retrieved sources involve meropenem/vaborbactam plus aztreonam. (academic.oup.com)
Initiation Thresholds or Indications
- Initiation is most defensible when a specific multidrug-resistant Gram-negative resistance mechanism is suspected (for example, metallo-β-lactamase production) and local susceptibility testing or phenotypic/molecular data support the likelihood of benefit from aztreonam-containing combination therapy. (pmc.ncbi.nlm.nih.gov)
Common Pitfalls to Avoid
- Avoid assuming synergy will occur in all isolates. (pmc.ncbi.nlm.nih.gov)
- Avoid using the combination as a substitute for susceptibility-informed antimicrobial selection when definitive susceptibility data are available. (No direct statistic or guideline statement found in retrieved sources.)
Target Blood Pressure
Not applicable.